Intellia Therapeutics

Intellia is a leading clinical-stage gene editing company developing CRISPR-based therapies. The company’s investigational in vivo programs use CRISPR to enable precise editing of disease-causing genes directly inside the human body. Intellia’s investigational ex vivo programs use CRISPR to engineer human cells outside the body for the treatment of cancer and autoimmune diseases.